New cancer clinical trial: pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Published on: July 25, 2018 at 12:00PM
Condition:   Prostate Cancer
Interventions:   Biological: pTVG-HP;   Drug: Nivolumab;   Drug: GM-CSF
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI);   Bristol-Myers Squibb;   Madison Vaccines Inc. (MVI)
Not yet recruiting
https://ift.tt/2LuLh0A